English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The investigation of novel EGFR and BRAF V600E dual inhibitors is intended to serve as targeted cancer treatment. Two sets of purine/pteridine-based derivatives were designed and synthesized as EGFR/BRAF V600E dual inhibitors. The majority of the compounds exhibited promising antiproliferative activity on the cancer cell lines tested. Compounds 5a , 5e , and 7e of purine-based and pteridine-based scaffolds were identified as the most potent hits in anti-proliferative screening, with GI 50 values of 38 nM, 46 nM, and 44 nM, respectively. Compounds 5a , 5e , and 7e demonstrated promising EGFR inhibitory activity, with IC 50 values of 87 nM, 98 nM, and 92 nM, respectively, when compared to erlotinib's IC 50 value of 80 nM. According to the results of the BRAF V600E inhibitory assay, BRAF V600E may not be a viable target for this class of organic compounds. Finally, molecular docking studies were carried out at the EGFR and BRAF V600E active sites to suggest possible binding modes.

Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAFV600E